Table 2 summarizes the results of studies investigating therapeutic drugs and targets for the induction of KCs with fatty acid in models of NAFLD and NASH in the past 5 years, the active ingredient involved eventually reduced the inflammation and progression of the disease, drugs targeting fibrosis caused by FFA-activated KCs remain to be investigated. The gene discussed is TBCE; the disease is metabolic dysfunction-associated steatohepatitis.